CTI BioPharma Corp. (CTIC)

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	75.77	53.95	0	0	3.35	26.29
Revenue Growth (YoY)	3201.48%	-	-	-	-87.28%	4.55%
Cost of Revenue	4.46	3.51	0	0	0	0
Gross Profit	71.31	50.43	0	0	3.35	26.29
Selling, General & Admin	88.69	84.83	56.2	17.63	19.16	22.06
Research & Development	39.06	36.9	39.14	25.94	24.11	36.47
Other Operating Expenses	-2.51	8.51	0	4.2	0.79	0.66
Operating Expenses	125.24	130.23	95.33	47.77	44.06	59.19
Operating Income	-53.93	-79.8	-95.33	-47.77	-40.71	-32.9
Interest Expense (Income)	15.26	13.14	2.42	0.83	1	1.21
Other Expense (Income)	0.05	0.06	0.16	3.85	-1.69	-4.79
Pretax Income	-69.24	-92.99	-97.91	-52.45	-40.02	-29.32
Net Income	-69.24	-92.99	-97.91	-52.45	-40.02	-29.32
Preferred Dividends	0	0	0	0	0	0.08
Net Income Common	-69.24	-92.99	-97.91	-52.45	-40.02	-29.4
Shares Outstanding (Basic)	132	115	90	71	58	56
Shares Outstanding (Diluted)	132	115	90	71	58	56
Shares Change	31.78%	27.27%	26.67%	22.71%	3.39%	53.86%
EPS (Basic)	-0.56	-0.81	-1.09	-0.74	-0.69	-0.52
EPS (Diluted)	-0.56	-0.81	-1.09	-0.74	-0.69	-0.52
Free Cash Flow	-82.32	-81.19	-84.89	-42.22	-27.82	-39.86
Free Cash Flow Per Share	-0.63	-0.71	-0.94	-0.59	-0.48	-0.71
Gross Margin	94.11%	93.49%	-	-	100.00%	100.00%
Operating Margin	-71.18%	-147.91%	-	-	-1217.07%	-125.14%
Profit Margin	-91.38%	-172.37%	-	-	-1196.41%	-111.83%
Free Cash Flow Margin	-108.64%	-150.50%	-	-	-831.75%	-151.61%
EBITDA	-51.83	-77.9	-94.97	-51.09	-38.47	-27.52
EBITDA Margin	-68.40%	-144.40%	-	-	-1150.13%	-104.67%
Depreciation & Amortization	2.15	1.95	0.53	0.53	0.55	0.59
EBIT	-53.98	-79.85	-95.49	-51.62	-39.02	-28.11
EBIT Margin	-71.24%	-148.02%	-	-	-1166.46%	-106.93%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).